[go: up one dir, main page]

UA91676C2 - Композиция, которая содержит ингибитор jnk и циклоспорин - Google Patents

Композиция, которая содержит ингибитор jnk и циклоспорин

Info

Publication number
UA91676C2
UA91676C2 UAA200610429A UAA200610429A UA91676C2 UA 91676 C2 UA91676 C2 UA 91676C2 UA A200610429 A UAA200610429 A UA A200610429A UA A200610429 A UAA200610429 A UA A200610429A UA 91676 C2 UA91676 C2 UA 91676C2
Authority
UA
Ukraine
Prior art keywords
cyclosporin
composition
jnk inhibitor
jnk
cancer
Prior art date
Application number
UAA200610429A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристиан Роммель
Пьер-Ален Вит
Original Assignee
Эплайд Рисерч Системз Эрс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эплайд Рисерч Системз Эрс Холдинг Н.В. filed Critical Эплайд Рисерч Системз Эрс Холдинг Н.В.
Publication of UA91676C2 publication Critical patent/UA91676C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение касается композиции, которая содержит ингибитор JNK и циклоспорин, в частности, для лечения нейронных расстройств, автоиммунных заболеваний, онкологических заболеваний и сердечно-сосудистых заболеваний.
UAA200610429A 2004-04-08 2005-04-08 Композиция, которая содержит ингибитор jnk и циклоспорин UA91676C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101468 2004-04-08
PCT/EP2005/051572 WO2005097116A1 (en) 2004-04-08 2005-04-08 Composition comprising a jnk inhibitor and cyclosporin

Publications (1)

Publication Number Publication Date
UA91676C2 true UA91676C2 (ru) 2010-08-25

Family

ID=34928946

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610429A UA91676C2 (ru) 2004-04-08 2005-04-08 Композиция, которая содержит ингибитор jnk и циклоспорин

Country Status (13)

Country Link
US (1) US20080039377A1 (ru)
EP (1) EP1850846A1 (ru)
JP (2) JP5080241B2 (ru)
KR (2) KR20120135441A (ru)
CN (1) CN1960726A (ru)
AU (2) AU2005230416B2 (ru)
BR (1) BRPI0509755A (ru)
CA (1) CA2561907A1 (ru)
EA (1) EA017893B1 (ru)
IL (1) IL178417A0 (ru)
NO (1) NO20065117L (ru)
UA (1) UA91676C2 (ru)
WO (1) WO2005097116A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP2026802A2 (en) * 2006-06-02 2009-02-25 Laboratoires Serono SA Jnk inhibitors for treatment of skin diseases
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
AU2008304313B2 (en) 2007-09-26 2013-01-10 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8828924B2 (en) * 2009-05-14 2014-09-09 University Of Maryland, Baltimore Methods of treating a diabetic embryopathy
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
CN117205331A (zh) * 2011-04-29 2023-12-12 西莱克塔生物科技公司 用于降低抗体应答的致耐受性合成纳米载体
US20140163075A1 (en) * 2011-06-01 2014-06-12 Netherland Cancer Institute Modulation of the ubiquitin-proteasome system (ups)
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
US10668053B2 (en) 2013-05-03 2020-06-02 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
KR102692773B1 (ko) 2014-09-07 2024-08-08 셀렉타 바이오사이언시즈, 인크. 유전자 편집 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
HUE072005T2 (hu) 2017-03-11 2025-10-28 Cartesian Therapeutics Inc Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények
KR20230164862A (ko) * 2022-05-26 2023-12-05 연세대학교 산학협력단 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
EP0296122B1 (en) * 1987-06-17 1993-09-29 Sandoz Ag Cyclosporins and their use as pharmaceuticals
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193267A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases

Also Published As

Publication number Publication date
AU2005230416A1 (en) 2005-10-20
CA2561907A1 (en) 2005-10-20
KR20060134198A (ko) 2006-12-27
BRPI0509755A (pt) 2007-10-16
AU2005230416B2 (en) 2010-05-13
EA200601841A1 (ru) 2007-04-27
AU2010212339A1 (en) 2010-09-09
JP5080241B2 (ja) 2012-11-21
IL178417A0 (en) 2007-02-11
CN1960726A (zh) 2007-05-09
AU2010212339B2 (en) 2012-07-19
KR20120135441A (ko) 2012-12-13
EA017893B1 (ru) 2013-04-30
NO20065117L (no) 2006-11-07
US20080039377A1 (en) 2008-02-14
JP2007532517A (ja) 2007-11-15
WO2005097116A1 (en) 2005-10-20
JP2012136550A (ja) 2012-07-19
EP1850846A1 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
UA91676C2 (ru) Композиция, которая содержит ингибитор jnk и циклоспорин
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
IL182417A0 (en) Mitotic kinesin inhibitors and methods of use thereof
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
PT1635824E (pt) Inibidores de p-38 à base de heterociclos de 5 membros
PT1742644E (pt) Composição terapêutica que contém pelo menos um derivado de pirrolobenzodiazepina e fludarabina
TW200510416A (en) P38 inhibitors and methods of use thereof
MXPA05013824A (es) Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL177849A0 (en) Methods and compositions for treatment of autoimmune diseases
WO2006055871A3 (en) Treatment for multiple sclerosis
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
EP1753445A4 (en) TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
AU2003206945A8 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
TW200735886A (en) Prevention and treatment of ocular side effects with a cyclosporin
IL181183A (en) Use of an elastase inhibitor in the manufacture of a medicament for the treatment of leukemia
SI1904048T1 (sl) Inhibitorji glepp-1 pri zdravljenju avtoimunskih in/ali vnetnih obolenj
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
IL181762A0 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
HK1102762A (en) Treatment of bipolar disorders and associated symptoms